STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

The sale does not mean a complete exit from oncology for GSK – it will continue with programmes in immunotherapy, epigenetics, and tumour environment. The deal with Novartis includes the ...

GSK shares fell on Wednesday after the group's vaccine sales continued to disappoint in the third quarter. The drugmaker saw weaker-than-expected demand for its respiratory syncytial virus (RSV ...

GSK is delivering consistent financial performance ... The Gardasil royalty loss impacted profit growth by minus 8% this quarter, meaning underlying operating profit was up 13%, demonstrating ...

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to the British drugmaker’s pipeline of potential treatments for lupus.

Luxury fashion and lifestyle group Kering, pharma giant GSK and building materials producer Holcim have become the first ...

GSK’s blockbuster hopes for depemokimab remain ... the total endoscopic nasal polyp score at 52 weeks as well as the mean nasal obstruction score from weeks 49 to 52. GSK is saving detailed ...

On Monday, GSK plc (NYSE:GSK) released headline results ... nasal polyp score at 52 weeks and a change from baseline in mean nasal obstruction score from weeks 49 to 52. Also Read: GSK’s Asthma ...

India's GlaxoSmithKline Pharmaceuticals reported a higher second-quarter adjusted profit on Tuesday, driven by strong demand for its generic drugs and vaccines.

GSK plc GSK announced positive data from the ... nasal polyp score at 52 weeks and the change from baseline in mean nasal obstruction score from weeks 49 to 52. Data from the studies showed ...

(Reuters) -GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third quarter, ...